Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

@article{Erickson2006AntibodymaytansinoidCA,
  title={Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.},
  author={Hans K. Erickson and Peter U. Park and Wayne C Widdison and Yelena V. Kovtun and Lisa M. Garrett and Karen Hoffman and Robert J. Lutz and Victor S. Goldmacher and Walter A. Bl{\"a}ttler},
  journal={Cancer research},
  year={2006},
  volume={66 8},
  pages={4426-33}
}
Antibody-drug conjugates are targeted anticancer agents consisting of a cytotoxic drug covalently linked to a monoclonal antibody for tumor antigen-specific activity. Once bound to the target cell-surface antigen, the conjugate must be processed to release an active form of the drug, which can reach its intracellular target. Here, we used both biological and biochemical methods to better define this process for antibody-maytansinoid conjugates. In particular, we examined the metabolic fate in… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 166 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Maytansine. Cancer Treat Rev 1978;5:199–207

  • BF Issell, ST Crooke
  • Research. on April
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…